Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Medium-high Risk Non-Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial

NCT07646145 is registered in ClinicalTrials.gov with Shanxi Province Cancer Hospital as lead sponsor.

NCT NCT07646145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07646145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Medium-high Risk Non-Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial
Lead sponsor
Shanxi Province Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2024
Completion date
April 30, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle-invasive bladder cancer (nmibc)